Evaluation of efficacy of antiviral therapy for chronic hepatitis C: A EUROHEP Consensus Report on response criteria

Journal of Viral Hepatitis

Volumn 3, Issue 5, 1996, Pages 273-276

  Craxi A ^a   Almasio, P ^b   Schalm, S ^b  

^a Cattedra di Medicina Interna   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS RNA;

BIOPSY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG THERAPY; HEPATITIS C; HUMAN; LIVER; PATHOLOGY; PREDICTION AND FORECASTING; STANDARD; TIME; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; BIOPSY; DRUG THERAPY; HEPATITIS C; HUMANS; LIVER; PREDICTIVE VALUE OF TESTS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030225398     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.1996.tb00055.x     Document Type: Article

References (14)

1. Terrault N, Wright T. Interferon and hepatitis C. N Engl J Med 1995; 332: 1509-1511.
2. Davis GL, Lau JYN. Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection. J Hepatol 1995; 22(Suppl.1): 110-114.
3. Zaaijer HL, Cuypers HTM, Reesink HW, Winkel IN, Gerken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993; 341: 722-724.
4. Reichard O, Glaumann H, Frydén A et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21: 918-922.
5. Lebovics E, Lantin J, Chaurushia G, Dworkin BM, Casellas A, Rosenthal WS. The breakthrough phenomenon during α-interferon therapy of chronic hepatitis C: Incidence, management, and outcome. Am J Gastroenterol 1995; 90: 951-954.
6. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
7. Pagliaro L, Craxì A, Cammá C et al. Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-828.
8. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1994; 330: 143.
9. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
10. Serfaty L, Giral P, Loria A, Andréani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-17.
11. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
12. Booth JCL, Foster GR, Kumar U et al. Chronic hepatitis C virus infections: Predictive value of genotype and level of viraemia on disease progression and response to interferon α. Gut 1995; 36: 427-432.
13. Yuki N, Hayashi N, Kasahara A et al. Pretreatment viral load and response to prolonged interferon-α course for chronic hepatitis C. J Hepatol 1995; 22: 457-463.
14. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3.